News | ZB-06 Vaginal Film Offers a New Approach to Contraception
A Woman-Controlled, Safe, and Effective Contraceptive Film
To meet global demand for effective contraception, monoclonal antibody company ZabBio developed ZB-06, a vaginal film containing an antisperm antibody. A study published in the American Journal of Obstetrics and Gynecology reported preliminary Phase 1 safety and efficacy results, offering promise for woman-controlled, nonhormonal contraception.
Background: The Need for New Options
About 842 million people worldwide use contraception, but the World Health Organization estimates that roughly 270 million still lack an effective method. Existing options include pills, implants, injections, patches, vaginal rings, intrauterine devices, and condoms, but each may have side effects. Hormonal methods may disrupt menstruation or affect future fertility, while conventional vaginal spermicides may disturb the vaginal microbiome and increase infection risk.
ZB-06 contains the humanized antibody HC4-N, which agglutinates and immobilizes sperm, preventing them from reaching the egg. It is a nonhormonal, nondetergent, on-demand method controlled by the woman.
Methods and Results
The study enrolled eight healthy women aged 18 to 50 who had undergone sterilization and had regular menstrual cycles. A postcoital test (PCT) assessed the film by measuring motile sperm in vaginal and cervical mucus.
Key findings included:
Motile sperm fell from an average of 26 per high-power field before use to 0.04 afterward;
The antisperm effect lasted more than 3 hours;
No film-related inflammation or disruption of vaginal flora was found;
The effect was reversible, with sperm activity returning to normal after discontinuation.
Significance and Limitations
ZB-06 appeared safe for both partners during short-term use and effectively prevented sperm from reaching the egg. However, the small study assessed only a single use, so larger trials and long-term safety research are needed.
Outlook
The study opens a path for woman-controlled, nonhormonal contraception and may provide another option in resource-limited regions. With further research, ZB-06 could become a safe, convenient, and effective family-planning tool.
News | ZB-06 Vaginal Film Offers a New Approach to Contraception
News | ZB-06 Vaginal Film Offers a New Approach to Contraception
A Woman-Controlled, Safe, and Effective Contraceptive Film
To meet global demand for effective contraception, monoclonal antibody company ZabBio developed ZB-06, a vaginal film containing an antisperm antibody. A study published in the American Journal of Obstetrics and Gynecology reported preliminary Phase 1 safety and efficacy results, offering promise for woman-controlled, nonhormonal contraception.
Background: The Need for New Options
About 842 million people worldwide use contraception, but the World Health Organization estimates that roughly 270 million still lack an effective method. Existing options include pills, implants, injections, patches, vaginal rings, intrauterine devices, and condoms, but each may have side effects. Hormonal methods may disrupt menstruation or affect future fertility, while conventional vaginal spermicides may disturb the vaginal microbiome and increase infection risk.
ZB-06 contains the humanized antibody HC4-N, which agglutinates and immobilizes sperm, preventing them from reaching the egg. It is a nonhormonal, nondetergent, on-demand method controlled by the woman.
Methods and Results
The study enrolled eight healthy women aged 18 to 50 who had undergone sterilization and had regular menstrual cycles. A postcoital test (PCT) assessed the film by measuring motile sperm in vaginal and cervical mucus.
Key findings included:
Motile sperm fell from an average of 26 per high-power field before use to 0.04 afterward;
The antisperm effect lasted more than 3 hours;
No film-related inflammation or disruption of vaginal flora was found;
The effect was reversible, with sperm activity returning to normal after discontinuation.
Significance and Limitations
ZB-06 appeared safe for both partners during short-term use and effectively prevented sperm from reaching the egg. However, the small study assessed only a single use, so larger trials and long-term safety research are needed.
Outlook
The study opens a path for woman-controlled, nonhormonal contraception and may provide another option in resource-limited regions. With further research, ZB-06 could become a safe, convenient, and effective family-planning tool.
Story source:
Collected online